Using the Incremental Net Benefit Framework for Quantitative Benefit–Risk Analysis in Regulatory Decision-Making—A Case Study of Alosetron in Irritable Bowel Syndrome

By Lynd Larry D.   Najafzadeh Mehdi   Colley Lindsey   Byrne Michael F.   Willan Andrew R.   Sculpher Mark J.   Johnson F. Reed   Hauber A. Brett  

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 411-417

Blackwell Publishing

Access to resources Recommend Favorite

Time Preferences for Health in Northern Tanzania: An Empirical Analysis of Alternative Discounting Models

By Robberstad Bjarne   Cairns John  

PharmacoEconomics, Vol. 25, Iss. 1, 2007-01 ,pp. : 73-88

Adis International

Access to resources Recommend Favorite

Model‐Based Assessment of Alternative Study Designs in Pediatric Trials. Part II: Bayesian Approaches

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 5, Iss. 8, 2016-08 ,pp. : 402-410

John Wiley & Sons Inc

Access to resources Recommend Favorite

Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies

By Zethraeus N.  

PharmacoEconomics, Vol. 21, Iss. 1, 2003-01 ,pp. : 39-48

Adis International

Access to resources Recommend Favorite

New study designs for new antipsychotics

By Kahn R.  

Psychopharmacology, Vol. 162, Iss. 1, 2002-06 ,pp. : 92-92

Springer Publishing Company

Access to resources Recommend Favorite